Issue 74 | September 2018

The results of Edelman’s Trust Barometer 2018 show trust in pharma is falling significantly, especially in informed public markets such as the US, Germany and France. But what is to blame for this drop in confidence and what needs to change?

Also, we delve into the highs and lows of Humira to understand how it became the world’s most successful drug and take a look at the innovative technology of BlueBird Bio, which was recently spotlighted by MIT Technology Review as one of the top 50 smartest companies, to find out more about its gene therapy focused business model and the work the company is doing to fight rare diseases. Plus, we examine the UK Government’s plan to build a fully automated drug discovery facility at the Rosalind Franklin Institute in Oxfordshire.

Finally, we explore current treatment options for chronic migraines including how the pharma industry is working to develop better therapies for the future, and profile the new philanthropic arm launched by the International Society of Pharmaceutical Engineering, the ISPE Foundation.


Editor | Eloise McLennan
Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Elly Earls, Chris Lo, Abi Millar, Sally Turner
Magazine Designer | Marzia Del Gaone

Graphic Designers | Paulius Zutautas, Marzia Compassi, Kate Cuntapay,

Anett Arc, Sara Basto, Ashley McPherson
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West


Sales Manager | Nimai Amin

+44 (0) 207 936 6453


Deputy Editor | Callum Tyndall

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registrationnumber 03171601.

All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.